Fig. 3
From: Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL
Relapse-free survival of patients with high-risk Ph-negative ALL based on NGS MRD dynamics within the first 6 months of frontline treatment.
